Up-to-date role of biologics in the management of respiratory syncytial virus

Seyhan Boyoglu-Barnum, Ralph A. Tripp

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)


Introduction: Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease in young children and a substantial contributor to respiratory tract disease throughout life. Despite RSV being a high priority for vaccine development, there is currently no safe and effective vaccine available. There are many challenges to developing an RSV vaccine and there are limited antiviral drugs or biologics available for the management of infection. In this article, we review the antiviral treatments, vaccination strategies along with alternative therapies for RSV. Areas covered: This review is a summary of the current antiviral and RSV vaccination approaches noting strategies and alternative therapies that may prevent or decrease the disease severity in RSV susceptible populations. Expert opinion: This review discusses anti-RSV strategies given that no safe and efficacious vaccines are available, and therapeutic treatments are limited. Various biologicals that target for RSV are considered for disease intervention, as it is likely that it may be necessary to develop separate vaccines or therapeutics for each at-risk population.

Original languageEnglish
Pages (from-to)1073-1082
Number of pages10
JournalExpert Opinion on Biological Therapy
Issue number9
Publication statusPublished - 1 Sept 2020
Externally publishedYes


Dive into the research topics of 'Up-to-date role of biologics in the management of respiratory syncytial virus'. Together they form a unique fingerprint.

Cite this